Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for prevention of paclitaxel-induced peripheral neuropathy in breast cancer
IRCT20180722040556N10Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer and chemotherapy-induced peripheral neuropathy (CIPN) comparing Curcumin with Placebo (2 arms). Primary endpoint: Incidence and severity of paclitaxel-induced peripheral neuropathy. Started Apr 2024; status: completed.
02
Drugs
curcumin
03
Conditions
breast cancerchemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on IRCT20180722040556N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180722040556N10.